172 related articles for article (PubMed ID: 37120837)
21. Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells.
Reif R; Haque F; Guo P
Nucleic Acid Ther; 2012 Dec; 22(6):428-37. PubMed ID: 23113765
[TBL] [Abstract][Full Text] [Related]
22. Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo.
Zhang QY; Ho PY; Tu MJ; Jilek JL; Chen QX; Zeng S; Yu AM
Int J Pharm; 2018 Aug; 547(1-2):537-544. PubMed ID: 29894758
[TBL] [Abstract][Full Text] [Related]
23. Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics.
Gangopadhyay S; Nikam RR; Gore KR
Nucleic Acid Ther; 2021 Aug; 31(4):245-270. PubMed ID: 33595381
[TBL] [Abstract][Full Text] [Related]
24. RNA Micelles for the Systemic Delivery of Anti-miRNA for Cancer Targeting and Inhibition without Ligand.
Yin H; Wang H; Li Z; Shu D; Guo P
ACS Nano; 2019 Jan; 13(1):706-717. PubMed ID: 30543397
[TBL] [Abstract][Full Text] [Related]
25. PEI-Coated Fe₃O₄ Nanoparticles Enable Efficient Delivery of Therapeutic siRNA Targeting REST into Glioblastoma Cells.
Wang R; Degirmenci V; Xin H; Li Y; Wang L; Chen J; Hu X; Zhang D
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30065155
[TBL] [Abstract][Full Text] [Related]
26. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
27. In vivo self-assembled small RNAs as a new generation of RNAi therapeutics.
Fu Z; Zhang X; Zhou X; Ur-Rehman U; Yu M; Liang H; Guo H; Guo X; Kong Y; Su Y; Ye Y; Hu X; Cheng W; Wu J; Wang Y; Gu Y; Lu SF; Wu D; Zen K; Li J; Yan C; Zhang CY; Chen X
Cell Res; 2021 Jun; 31(6):631-648. PubMed ID: 33782530
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
29. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
Sivakumar P; Kim S; Kang HC; Shim MS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
[TBL] [Abstract][Full Text] [Related]
30. Sphk2 RNAi nanoparticles suppress tumor growth via downregulating cancer cell derived exosomal microRNA.
Liang J; Zhang X; He S; Miao Y; Wu N; Li J; Gan Y
J Control Release; 2018 Sep; 286():348-357. PubMed ID: 30077738
[TBL] [Abstract][Full Text] [Related]
31. Utilizing RNA nanotechnology to construct negatively charged and ultrasound-responsive nanodroplets for targeted delivery of siRNA.
Guo L; Shi D; Shang M; Sun X; Meng D; Liu X; Zhou X; Li J
Drug Deliv; 2022 Dec; 29(1):316-327. PubMed ID: 35037525
[TBL] [Abstract][Full Text] [Related]
32. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles.
Jin J; Bae KH; Yang H; Lee SJ; Kim H; Kim Y; Joo KM; Seo SW; Park TG; Nam DH
Bioconjug Chem; 2011 Dec; 22(12):2568-72. PubMed ID: 22070554
[TBL] [Abstract][Full Text] [Related]
33. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
Traber GM; Yu AM
J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
[TBL] [Abstract][Full Text] [Related]
34. Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for In Vivo Gene Silencing in Leukemia.
Lee DJ; Kessel E; Lehto T; Liu X; Yoshinaga N; Padari K; Chen YC; Kempter S; Uchida S; Rädler JO; Pooga M; Sheu MT; Kataoka K; Wagner E
Bioconjug Chem; 2017 Sep; 28(9):2393-2409. PubMed ID: 28772071
[TBL] [Abstract][Full Text] [Related]
35. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
[TBL] [Abstract][Full Text] [Related]
36. Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA.
Zhang L; Mu C; Zhang T; Yang D; Wang C; Chen Q; Tang L; Fan L; Liu C; Shen J; Li H
J Nanobiotechnology; 2021 Jan; 19(1):13. PubMed ID: 33413427
[TBL] [Abstract][Full Text] [Related]
37. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2.
Zheng M; Morgan-Lappe SE; Yang J; Bockbrader KM; Pamarthy D; Thomas D; Fesik SW; Sun Y
Cancer Res; 2008 Sep; 68(18):7570-8. PubMed ID: 18794145
[TBL] [Abstract][Full Text] [Related]
38. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
Weinstein S; Toker IA; Emmanuel R; Ramishetti S; Hazan-Halevy I; Rosenblum D; Goldsmith M; Abraham A; Benjamini O; Bairey O; Raanani P; Nagler A; Lieberman J; Peer D
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E16-22. PubMed ID: 26699502
[TBL] [Abstract][Full Text] [Related]
39. MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties.
Lin JC; Tsai JT; Chao TY; Ma HI; Chien CS; Liu WH
Radiother Oncol; 2018 Nov; 129(2):352-363. PubMed ID: 30322656
[TBL] [Abstract][Full Text] [Related]
40. A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy.
Jang M; Han HD; Ahn HJ
Sci Rep; 2016 Aug; 6():32363. PubMed ID: 27562435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
